Skip to content
Open access

Real world genomic profiling in non-small cell lung cancer reveals regional variations with clinical implications

Sep 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 46 references
Medicine

TL;DR

Routine genomic profiling in NSCLC provides clinically relevant information beyond actionable driver detection when interpreted together with stage, smoking history, age, sex, and regional molecular context, and support a more context-aware interpretation of routine molecular diagnostics in thoracic oncology.

Abstract

Background Routine targeted genomic profiling in non-small cell lung cancer (NSCLC) is primarily used to identify actionable alterations but may provide more information for clinical decision making. In this study routine genomic profiling data were used to examine the mutational landscape of lung cancer and its relationship to patient characteristics. Materials and methods We analyzed Archer VariantPlex 67-gene sequencing data from 528 patients diagnosed with lung cancer in the North Swedish Health Care Region between 2011 and 2021 and linked the genomic results to registry-derived clinical and demographic data. Mutation frequencies, positional architectures, subgroup enrichments, and survival associations were compared within the regional cohort and against an external reference cohort assembled from cBioPortal. Results After quality filtering, 1,415 somatic variants across 60 genes were identified, with a mean of 2.68 mutations per tumor, indicating substantial heterogeneity in mutational profiles. TP53 and KRAS formed a conserved mutational backbone across cohorts, whereas EGFR was less frequent and MET, APC, ATM, and CDKN2A were enriched in North Sweden relative to the external reference cohort. Major hotspot architectures were broadly preserved, although MET showed the clearest positional divergence. Mutation patterns varied by age, sex, smoking status, and disease stage. EGFR defined the most coherent clinical subtype, being enriched in females, never-smokers, younger patients, and earlier-stage disease, whereas KRAS, STK11, and TP53 were associated with smoking. EGFR was the strongest favorable prognostic marker, but stage strongly influenced the interpretation of many survival differences, indicating that gene-level prognostic signals are closely shaped by clinical context. Conclusions Routine genomic profiling in NSCLC provides clinically relevant information beyond actionable driver detection when interpreted together with stage, smoking history, age, sex, and regional molecular context. These findings support a more context-aware interpretation of routine molecular diagnostics in thoracic oncology.

Read PDF

Similar papers

Review Open access Aug 2026

Genomic alterations in pediatric tumors: clinical relevance and translational insights.

BACKGROUND Cancer is the leading cause of disease-related mortality in children. Next-generation sequencing (NGS) has emerged as a critical tool in precision oncology, enabling the identification of somatic genomic alterations that may inform diagnosis, prognosis, and therapy. This study evaluated the clinical utility...

H. Cohen, Iris Kventsel, S. Caspi et al. · 0 citations
Open access Oct 2026

Clinical Utility of Broad-Panel Profiling in Non-Small Cell Lung Cancer: Pairwise Co-Mutational Gene Patterns and PD-L1 Associations Define Stage-Specific Prognosis

Objectives: Precision medicine has improved outcomes in advanced lung cancer, but its implementation remains limited. The prospective LANTERN project (NCT05802771) involves comprehensive clinical and multi-omics data collection. Here, we report preliminary genomic findings, focusing on the prognostic impact of gene mut...

C. Sassorossi, E. De Paolis, Jessica Evangelista et al. · 0 citations
Open access Aug 2026

Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer

The routine implementation of comprehensive genomic profiling in metastatic HER2-negative breast cancer, especially in metastatic HER2-negative breast cancer, is supported to guide precision oncology strategies and enable enrollment in biomarker-driven clinical trials.

E. Papadopoulou, M. Stathoulopoulou, M. Matiatou et al. · 0 citations
Open access Sep 2026

Real-World Landscape of BRCA Deleterious Alterations in Advanced Prostate Cancer: Insights From a Nationwide Genomic Database.

BACKGROUND The clinical characteristics of BRCA1 and BRCA2 (BRCA) deleterious alterations in advanced prostate cancer-considering age, family history, co-occurring gene alterations, and variant type-remain incompletely understood in patients undergoing tumor-only panel testing. MATERIALS AND METHODS We analyzed 2,815...

H. Tsumura, D. Koguchi, K. Tabata et al. · 0 citations
Open access Sep 2026

Genomic alterations and co-mutation patterns in advanced NSCLC: a real-world DNA-based NGS study in a large Turkish cohort

A large-scale real-world study demonstrates the heterogeneous molecular landscape of advanced NSCLC and identifies clinically relevant co-alteration patterns involving EGFR, KRAS, STK11, MET, and PIK3CA involving EGFR, which highlight the value of DNA-based NGS profiling for characterizing the genomic landscape and rec...

Aysu Sadioğlu, O. Ekinci, Nalan Akyurek · 0 citations
Open access Sep 2026

Distinct genomic landscape of non-small cell lung cancer in Bangladeshi patients: Implications for precision oncology in a resource-limited setting

Highlights • Next-generation sequencing (NGS) on circulating tumor DNA (ctDNA) from 106 Bangladeshi NSCLC patients has been performed.• We found mutations in 85.8% of patients, and the most common mutated genes are TP53, EGFR, and KRAS.• We could identify most prevalent clinically important pathogenic variants, c.2155G...

Md. Al Amin, Manisha Das, Pradip Kumar Nath et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.